RAPID Pharmaceuticals is a privately held Swiss biopharmaceutical company developing novel therapeutics consisting of small peptides for infectious (illnesses) diseases, neurodegenerative diseases (conditions), and inflammatory diseases.

RAPID has developed a novel and unique platform of peptide therapeutics targeting cell surface receptors that are key to many major diseases. Our peptide therapeutics bind to the cell surface receptors to block disease pathways without disrupting the natural cell processes.

RAPID has proprietary technology to discover, develop, and manufacture stable peptide-based medicines for parenteral, nasal, and oral administration. Our patented technologies allow us to synthesize short receptor-active peptides derived from larger human or viral proteins that we modify and stabilize into potent bioactive compounds.

These innovative compounds are being developed as systemic mediators to regulate cell communication within and among the nervous, immune, and glandular systems. In this way we are creating novel therapies for many of the most challenging chronic degenerative diseases of our time that are still largely untreatable.

Our Therapeutic Focus:

  • Progressive Multifocal Leukoencephalopathy (PML)
  • Immune Reconstitution Inflammatory Syndrom (IRIS)
  • Multiple Sclerosis (MS)
  • Alzheimer’s Disease (AD)
  • Autism Spectrum Disorders (ASD)
  • Minor Traumatic Brain Injury (MTBI)
  • Neuropathic Pain/Diabetic Peripheral Neuropathy

Receptor Active Peptides into Drugs